Two phosphopeptides are currently being tested in melanoma patients, one derived from the insulin receptor substrate 2 (IRS2) and the other from breast cancer antiestrogen resistance 3 (BCAR3) (NCT01846143). The gene discussed is IRS2; the disease is melanoma.